Last $1.01 USD
Change Today +0.02 / 2.02%
Volume 223.5K
AVEO On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 10/17/14 All times are local (Market data is delayed by at least 15 minutes).

aveo pharmaceuticals inc (AVEO) Snapshot

Open
$1.01
Previous Close
$0.99
Day High
$1.03
Day Low
$0.97
52 Week High
10/24/13 - $2.35
52 Week Low
10/13/14 - $0.85
Market Cap
52.8M
Average Volume 10 Days
313.9K
EPS TTM
$-1.06
Shares Outstanding
52.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AVEO PHARMACEUTICALS INC (AVEO)

aveo pharmaceuticals inc (AVEO) Related Businessweek News

No Related Businessweek News Found

aveo pharmaceuticals inc (AVEO) Details

AVEO Pharmaceuticals, Inc., doing business as AVEO Oncology, a biopharmaceutical company, is engaged in discovering, developing, and commercializing targeted cancer therapies using its Human Response Platform. Its therapeutic candidates under development program include AV-203, an anti-ErbB3 monoclonal antibody that has completed a Phase 1 dose escalation study; Ficlatuzumab, a hepatocyte growth factor inhibitory antibody, which is in Phase 2 trial; Tivozanib, an investigational tyrosine kinase inhibitor of various vascular endothelial growth factor receptors; and AV-380 Program, a program focusing on cachexia, a serious and common complication of advanced cancer, as well as a range of chronic diseases that is characterized by unintentional weight loss, progressive muscle wasting, and a loss of appetite. AVEO Pharmaceuticals, Inc. has strategic partnerships with St. Vincent’s Hospital Sydney Limited; Kyowa Hakko Kirin; Biogen Idec, Inc.; OSI Pharmaceuticals, Inc.; Centocor Ortho Biotech Inc.; and Merck & Co., Inc. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

71 Employees
Last Reported Date: 03/13/14
Founded in 2001

aveo pharmaceuticals inc (AVEO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $567.9K
Chief Scientific Officer
Total Annual Compensation: $334.5K
Compensation as of Fiscal Year 2013.

aveo pharmaceuticals inc (AVEO) Key Developments

AVEO Oncology and Biodesix, Inc. Announces Presentation of Results from A Retrospective Exploratory Analysis Using Veristrat

AVEO Oncology and Biodesix, Inc. announced the presentation of results from a retrospective exploratory analysis using VeriStrat, a commercially available serum protein test, to identify patients most likely to benefit from the addition of ficlatuzumab, AVEO's HGF inhibitory antibody, to epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) therapy in a randomized Phase 2 study of ficlatuzumab and gefitinib (IRESSA) in previously untreated Asian subjects with non-small cell lung cancer (NSCLC). The results, presented in a poster session (abstract #8195) at the 2014 Congress of the European Society for Medical Oncology (ESMO), suggest that VeriStrat may be selective of positive clinical response for ficlatuzumab plus gefitinib over gefitinib alone. A total of 188 patients were enrolled in a randomized Phase 2 study (P6162) designed to compare the combination of ficlatuzumab and gefitinib with gefitinib alone in treatment-naïve Asian patients with non-small cell lung adenocarcinoma. For this retrospective exploratory analysis, 180 serum samples were assigned a VeriStrat label of either "Good" (VSG) or "Poor" (VSP) (VSG=145, VSP=35). While the study failed to demonstrate improved overall survival (OS) or progression-free survival (PFS) over gefitinib alone in the intent-to-treat population, the addition of ficlatuzumab to gefitinib provided significant clinical benefit to the VSP subgroup. No benefit was observed in the VSG subgroup in either OS (Median 24.7 mo for ficlatuzumab + gefitinib [n=69] vs not reached for gefitinib alone [n=76]; HR 1.18, p=0.492) or PFS (Median 5.6 mo for ficlatuzumab + gefitinib vs 5.6 mo for gefitinib alone; HR 1.06, p=0.753). Despite the small sample sizes, similar patterns in OS and PFS based on VeriStrat stratification were also observed in patients with known EGFR mutations (n=71) and VSP classification (n=11). Based on these data, in April 2014, AVEO and Biodesix(R) entered into a worldwide agreement to develop and commercialize ficlatuzumab with a Biodesix companion diagnostic test. As part of this agreement, AVEO and Biodesix plan to conduct a confirmatory Phase 2 study using a Biodesix VeriStrat "Poor" classification as a selective biomarker for the combination of ficlatuzumab and an EGFR-TKI, versus an EGFR TKI alone, in previously untreated, EGFR mutation-positive patients with advanced non-small-cell lung cancer. The study is expected to initiate before year-end.

AVEO Oncology Announces Presentation of AV-380 Preclinical Data at 2(nd) Cancer Cachexia Conference

AVEO Oncology announced the presentation of results from four preclinical studies of AV-380, the Company's potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), in various in vivo cachexia models and in vitro assays at the 2(nd) Cancer Cachexia Conference, being held September 26-28, 2014, in Montreal, Canada. AV-380 is a potential first-in-class GDF15 inhibitor, discovered using AVEO's proprietary Human Response Platform(TM), that provides the company unique insights into cancer and related disease biology. The first-in-human clinical trial of AV-380 is planned for the second half of 2015. Initial clinical development is expected to be for the treatment of cancer cachexia. AVEO plans to evaluate opportunities for partnerships to expand the development of AV-380, including in cachexia associated with non-cancer indications, including chronic heart failure, chronic kidney disease and chronic obstructive pulmonary disease to leverage the full potential of this asset. Cachexia: Cachexia is a serious and common complication in patients with advanced cancer and other chronic diseases, characterized by symptoms of unintentional weight loss, progressive muscle wasting and loss of appetite (anorexia). Cachexia affects some five million individuals in the United States. It is estimated that 60-80% of patients with advanced cancer have cachexia and approximately 30% of cancer patients die due to cachexia. AVEO: AVEO Oncology is a biopharmaceutical company committed to discovering and developing targeted therapies designed to provide substantial impact in the lives of people with cancer by addressing unmet medical needs. AVEO's proprietary Human Response Platform(TM) provides the company unique insights into cancer and related disease biology and is being leveraged in the discovery and clinical development of its therapeutic candidates.

AVEO Oncology Announces Lease Termination and Amendment to Debt Financing Facility

AVEO Oncology announced that, as part of its plan to decrease operational expenses, the Company has entered into a termination of its lease agreement pertaining to the Company's headquarters in Cambridge, Massachusetts, reducing its existing lease obligations by $110 million. In addition, the Company has amended its debt financing facility with Hercules Technology Growth Capital (HTGC). Combined, these transactions do not impact the Company's prior financial guidance, with existing cash, cash equivalents and marketable securities providing resources to fund its operating plan into the fourth quarter of 2015 with an expected 2014 year-end cash balance of $50-55 million. Under the terms of its amended lease agreement with BMR-650 E Kendall B LLC, AVEO will terminate its long term lease dated May 9, 2012, in exchange for a termination fee of approximately $7.8 million due upon execution of the agreement, and $7.8 million payable over the subsequent nine months. AVEO will immediately vacate the unused portions of its premises at 650 East Kendall St. and will exit the remaining occupied portions of its premises within twelve months. Pursuant to its amended loan agreement with HTGC, AVEO has received a new $10 million loan, which is in addition to an outstanding principal of $11.6 million from an existing loan agreement. The new loan carries an interest only repayment period of twelve months, with the ability to extend such period for up to an additional twelve months based on the achievement of certain milestones, and has a maturity date of January 1, 2018. The existing loan carries an interest only period of three months, and is expected to be fully repaid by December 2015. In conjunction with the new loan, the Company has issued a warrant to purchase an aggregate of 608,696 shares of AVEO's common stock, at a price of $1.15 per share.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AVEO:US $1.01 USD +0.02

AVEO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ArQule Inc $1.15 USD +0.02
Bristol-Myers Squibb Co $50.42 USD +1.20
Exelixis Inc $1.58 USD -0.045
GlaxoSmithKline SAE £12.94 EGP -1.06
Takeda Pharmaceutical Co Ltd ¥4,476 JPY +138.00
View Industry Companies
 

Industry Analysis

AVEO

Industry Average

Valuation AVEO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.9x
Price/Book 1.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AVEO PHARMACEUTICALS INC, please visit www.aveopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.